Get started

Richtvlive

Terran Orbital Corp (NYSE: LLAP)Terran Orbital Corp (NYSE: LLAP) Q1 2023 Financial Results I like this company for the long term revenue growth potential 2.5 billion in backlog - I do not own this stock yet but I am watching it closely for a long term entry $28.2 million first quarter 2023 revenues, up 115% year over year #llap #news #richtvlive Over $2.5 billion and with a record 360 satellites in backlog as of quarter end Announcing a new $87 million constellation order Guiding FY2023 revenue in excess of $250 million BOCA RATON, Fla.--(BUSINESS WIRE)-- Terran Orbital Corporation (NYSE: LLAP) ("Terran Orbital" or the "Company"), a leading manufacturer of satellite products primarily serving the aerospace and defense industries, today announced financial results and operational highlights for the three months ended March 31, 2023. Terran Orbital Corp (NYSE: LLAP) Q1 2023 Financial Results First Quarter 2023 Highlights Generated $28.2 million of revenue with contribution from over 20 programs Backlog of over $2.5 billion represents over 1,300% increase since December 31, 2022 Expansion of capacity on track – commissioning new 50 Tech facility Net loss of $54.4 million improved from net loss of $71.4 million in 1Q22 Subsequent Events Received initial milestone payment under contract with Rivada Space Networks Awarded $87 million, 16 satellite order from a new customer Marc Bell, Co-Founder, Chairman & CEO, said, “I am excited to announce our record recent awards and solid operational progress. Our momentum in new constellation awards and over 30 programs on contract today sets the stage for us to harvest the benefits of our strategic investments in capacity ahead of the market’s explosion of demand. We are building a new satellite production system that will have a level of scale, vertical integration, and automation not available today. Our production system is designed to deliver satellites at mass scale at the speed and quality our customers desire, at a price point to stimulate new markets, and at margins to reward our shareholders. Our newest expansion will be coming online in the next few weeks and our next capacity increase is on schedule for a fall 2024 opening.”
LLong
by richtvlive
BriaCell Therapeutics Corp | Bria-MT™ | NASDAQ: BCTX TSX: BCTBriacell Therapeutics Corp has been trending higher on news - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) #briacell #cancer #richtv #richtvlive #breastcancer (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is presenting positive clinical data from its lead product candidate, Bria-IMT™, summarized in four poster sessions during the 2023 American Association for Cancer Research (AACR) Annual Meeting held from April 14 – 19, 2023 at Orange County Convention Center, Orlando, Florida. “Our data highlights the potential clinical value of the Bria-MT™ regimen in patients with advanced metastatic breast cancer after receiving multiple prior therapies,” said Carmen Calfa, M.D., of the Sylvester Comprehensive Cancer Center at the University of Miami, Associate Professor of Clinical Medicine, Principal Clinical Investigator, and co-author of the study of Bria-IMT™ in combination with PD-1 inhibitors pembrolizumab and retifanlimab. “These results are promising and the fact that patients have had a great quality of life thus far is remarkable. We are hopeful that this novel immunotherapy proves to be an effective therapy for our patients.” “Our clinical findings continue to confirm our approach for our upcoming pivotal trial of Bria-IMT™ combination regimen,” commented Dr. William V. Williams, BriaCell’s President and CEO. “With over 40,000 annual deaths in the U.S. alone, advanced metastatic breast cancer remains an unmet medical need. Patients who have only months to live tend to avoid current therapies that are proven ineffective and are associated with excessive toxicities. BriaCell’s regimen has shown robust clinical efficacy, better than expected survival outcomes, and an excellent safety profile in this very difficult to treat patient cohort. We are seeing benefits in patients who failed other treatments and/or cannot tolerate the harsh side effects of other therapies.”
NASDAQ:BCTX
by richtvlive